Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- Author
- ELLIS, Matthew J; SUMAN, Vera J; ESSERMAN, Laura J; UNZEITIG, Gary W; MARGENTHALER, Julie; BABIERA, Gildy V; KELLY MARCOM, P; GUENTHER, Joseph M; WATSON, Mark A; LEITCH, Marilyn; HUNT, Kelly; OLSON, John A; HOOG, Jeremy; LI LIN; SNIDER, Jacqueline; PRAT, Aleix; PARKER, Joel S; JINGQIN LUO; DESCHRYVER, Katherine; CRAIG ALLRED, D
[1] Siteman Cancer Center; Washington University, St Louis, MO, United States
[2] American College of Surgeons Oncology Group Statistical Center, Mayo Clinic, Rochester, MN, United States
[3] Linberger Cancer Center, University of North Carolina, Chapel Hill, United States
[4] Duke University Cancer Center, Durham, NC, United States
[5] Helen Diller Cancer Center, University of California San Francisco, San Francisco, CA, United States
[6] Doctors Hospital of Laredo, Laredo, United States
[7] University of Texas MD Anderson Cancer Center, Houston, United States
[8] Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, United States
[9] Good Samaritan Hospital, Cincinnati, OH, United States - Source
Journal of clinical oncology. 2011, Vol 29, Num 17, pp 2342-2349, 8 p ; ref : 26 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- American Society of Clinical Oncology, Alexandria, VA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Adulte Anastrozole Anticancéreux Cancer du sein Cancérologie Essai clinique phase II Etude comparative Exémestane Femelle Femme Homme Létrozole Marqueur biologique Postménopause Pronostic Randomisation Récepteur hormonal Récepteur oestrogène Soustype Stade clinique Traitement néoadjuvant Valeur prédictive Antihormone Antioestrogène Cancer Composé non stéroïde Dérivé d'azole Dérivé de l'androstane Dérivé du triazole Enzyme Estrogen synthase Inhibiteur de l'aromatase Inhibiteur enzyme Pathologie de la glande mammaire Pathologie du sein Stéroïde Tumeur maligne
- Keyword (en)
- Adult Anastrozole Antineoplastic agent Breast cancer Cancerology Phase II trial Comparative study Exemestane Female Woman Human Letrozole Biological marker Postmenopause Prognosis Randomization Hormonal receptor Estrogen receptor Subtype Clinical stage Neoadjuvant treatment Predictive value Antihormone Antiestrogen Cancer Non steroid compound Azole derivatives Androstane derivatives Triazole derivatives Enzyme Estrogen synthase Aromatase inhibitor Enzyme inhibitor Mammary gland diseases Breast disease Steroid Malignant tumor
- Keyword (es)
- Adulto Anastrozol Anticanceroso Cáncer del pecho Cancerología Ensayo clínico fase II Estudio comparativo Exemestano Hembra Mujer Hombre Letrozol Marcador biológico Postmenopausia Pronóstico Aleatorización Receptor hormonal Receptor estrógeno Subtipo Estadio clínico Neocoadyuvante tratamiento Valor predictivo Antihormona Antiestrógeno Cáncer Compuesto no esteroide Azol derivado Androstano derivado Triazol derivado Enzima Estrogen synthase Inhibidor aromatase Inhibidor enzima Glándula mamaria patología Seno patología Esteroide Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24241954
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2010.31.6950 
https://dx.doi.org/10.1200/JCO.2010.31.6950
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.31.6950\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2342\";s:8:\"\u0000*\u0000epage\";s:4:\"2349\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ELLIS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Matthew J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"SUMAN, Vera J\";i:1;s:17:\"ESSERMAN, Laura J\";i:2;s:16:\"UNZEITIG, Gary W\";i:3;s:19:\"MARGENTHALER, Julie\";i:4;s:16:\"BABIERA, Gildy V\";i:5;s:15:\"KELLY MARCOM, P\";i:6;s:18:\"GUENTHER, Joseph M\";i:7;s:14:\"WATSON, Mark A\";i:8;s:15:\"LEITCH, Marilyn\";i:9;s:11:\"HUNT, Kelly\";i:10;s:13:\"OLSON, John A\";i:11;s:12:\"HOOG, Jeremy\";i:12;s:6:\"LI LIN\";i:13;s:18:\"SNIDER, Jacqueline\";i:14;s:11:\"PRAT, Aleix\";i:15;s:14:\"PARKER, Joel S\";i:16;s:11:\"JINGQIN LUO\";i:17;s:21:\"DESCHRYVER, Katherine\";i:18;s:15:\"CRAIG ALLRED, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.31.6950\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2342\";s:8:\"\u0000*\u0000epage\";s:4:\"2349\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ELLIS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Matthew J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"SUMAN, Vera J\";i:1;s:17:\"ESSERMAN, Laura J\";i:2;s:16:\"UNZEITIG, Gary W\";i:3;s:19:\"MARGENTHALER, Julie\";i:4;s:16:\"BABIERA, Gildy V\";i:5;s:15:\"KELLY MARCOM, P\";i:6;s:18:\"GUENTHER, Joseph M\";i:7;s:14:\"WATSON, Mark A\";i:8;s:15:\"LEITCH, Marilyn\";i:9;s:11:\"HUNT, Kelly\";i:10;s:13:\"OLSON, John A\";i:11;s:12:\"HOOG, Jeremy\";i:12;s:6:\"LI LIN\";i:13;s:18:\"SNIDER, Jacqueline\";i:14;s:11:\"PRAT, Aleix\";i:15;s:14:\"PARKER, Joel S\";i:16;s:11:\"JINGQIN LUO\";i:17;s:21:\"DESCHRYVER, Katherine\";i:18;s:15:\"CRAIG ALLRED, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.31.6950\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.31.6950\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2342\";s:8:\"\u0000*\u0000epage\";s:4:\"2349\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ELLIS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Matthew J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"SUMAN, Vera J\";i:1;s:17:\"ESSERMAN, Laura J\";i:2;s:16:\"UNZEITIG, Gary W\";i:3;s:19:\"MARGENTHALER, Julie\";i:4;s:16:\"BABIERA, Gildy V\";i:5;s:15:\"KELLY MARCOM, P\";i:6;s:18:\"GUENTHER, Joseph M\";i:7;s:14:\"WATSON, Mark A\";i:8;s:15:\"LEITCH, Marilyn\";i:9;s:11:\"HUNT, Kelly\";i:10;s:13:\"OLSON, John A\";i:11;s:12:\"HOOG, Jeremy\";i:12;s:6:\"LI LIN\";i:13;s:18:\"SNIDER, Jacqueline\";i:14;s:11:\"PRAT, Aleix\";i:15;s:14:\"PARKER, Joel S\";i:16;s:11:\"JINGQIN LUO\";i:17;s:21:\"DESCHRYVER, Katherine\";i:18;s:15:\"CRAIG ALLRED, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.31.6950\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2342\";s:8:\"\u0000*\u0000epage\";s:4:\"2349\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ELLIS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Matthew J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"SUMAN, Vera J\";i:1;s:17:\"ESSERMAN, Laura J\";i:2;s:16:\"UNZEITIG, Gary W\";i:3;s:19:\"MARGENTHALER, Julie\";i:4;s:16:\"BABIERA, Gildy V\";i:5;s:15:\"KELLY MARCOM, P\";i:6;s:18:\"GUENTHER, Joseph M\";i:7;s:14:\"WATSON, Mark A\";i:8;s:15:\"LEITCH, Marilyn\";i:9;s:11:\"HUNT, Kelly\";i:10;s:13:\"OLSON, John A\";i:11;s:12:\"HOOG, Jeremy\";i:12;s:6:\"LI LIN\";i:13;s:18:\"SNIDER, Jacqueline\";i:14;s:11:\"PRAT, Aleix\";i:15;s:14:\"PARKER, Joel S\";i:16;s:11:\"JINGQIN LUO\";i:17;s:21:\"DESCHRYVER, Katherine\";i:18;s:15:\"CRAIG ALLRED, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2010.31.6950\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2342\";s:8:\"\u0000*\u0000epage\";s:4:\"2349\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"ELLIS\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Matthew J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"SUMAN, Vera J\";i:1;s:17:\"ESSERMAN, Laura J\";i:2;s:16:\"UNZEITIG, Gary W\";i:3;s:19:\"MARGENTHALER, Julie\";i:4;s:16:\"BABIERA, Gildy V\";i:5;s:15:\"KELLY MARCOM, P\";i:6;s:18:\"GUENTHER, Joseph M\";i:7;s:14:\"WATSON, Mark A\";i:8;s:15:\"LEITCH, Marilyn\";i:9;s:11:\"HUNT, Kelly\";i:10;s:13:\"OLSON, John A\";i:11;s:12:\"HOOG, Jeremy\";i:12;s:6:\"LI LIN\";i:13;s:18:\"SNIDER, Jacqueline\";i:14;s:11:\"PRAT, Aleix\";i:15;s:14:\"PARKER, Joel S\";i:16;s:11:\"JINGQIN LUO\";i:17;s:21:\"DESCHRYVER, Katherine\";i:18;s:15:\"CRAIG ALLRED, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:284:\"Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype\u2014ACOSOG Z1031\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
